COVID pneumonia is a lung infection caused by the SARS-CoV-2 virus that damages the tiny air sacs (alveoli) where oxygen enters your bloodstream. Unlike typical bacterial pneumonia, which tends to affect one section of the lung, COVID pneumonia usually spreads across both lungs simultaneously and can cause a distinctive pattern of oxygen deprivation that sometimes goes unnoticed until it becomes severe.
How COVID Pneumonia Damages the Lungs
The virus targets specific cells lining the air sacs deep in your lungs. Once inside these cells, it kills them and triggers a chain reaction: the dying cells release chemical signals that damage neighboring cells, break down the barriers between your air sacs and blood vessels, and recruit waves of immune cells to the area. Those immune cells, primarily a type called macrophages, then release their own inflammatory signals that cause even more cell death. This cascading damage is what makes COVID pneumonia so different from a straightforward bacterial infection, where the damage is more localized.
The result is something pathologists call diffuse alveolar damage. Fluid and protein leak into the air sacs, forming a coating called a hyaline membrane that blocks oxygen from passing into the blood. At the same time, the blood vessels in the lungs become inflamed and can develop tiny clots. This combination of flooded air sacs and disrupted blood flow is what makes breathing so difficult and why patients sometimes need high levels of oxygen support.
Symptoms and Silent Hypoxia
The core symptoms of COVID pneumonia are fever, persistent cough, fatigue, and shortness of breath. These can develop anywhere from 5 to 10 days after initial COVID symptoms appear. Many patients describe a tightness in the chest or feeling winded doing things that normally wouldn’t be difficult, like walking across a room.
One of the most dangerous features of COVID pneumonia is silent hypoxia, where blood oxygen levels drop dangerously low without the expected feeling of gasping or struggling to breathe. In the early stages, patients may unconsciously breathe faster to compensate, which temporarily masks the severity of the problem. Pulse oximeters, the fingertip devices that measure oxygen saturation, can also overestimate how much oxygen is actually in your blood during this phase. By the time the oximeter reading visibly drops, the situation may already be critical. This is why COVID pneumonia caught many patients and doctors off guard early in the pandemic, and why oxygen monitoring remains important for anyone with a confirmed COVID infection and worsening symptoms.
What It Looks Like on Imaging
CT scans of COVID pneumonia have a characteristic appearance that radiologists learned to recognize quickly. The hallmark is ground-glass opacities, areas of hazy whiteness in the lungs that look like frosted glass. These patches typically appear on both sides, cluster toward the outer edges and lower portions of the lungs, and often have a rounded shape. In more advanced cases, these hazy areas become denser (consolidation) or develop a pattern called “crazy paving,” where the ground-glass areas are overlaid with a network of thickened lines resembling cracked pavement.
A later-stage pattern called the reverse halo can also appear: a ring of dense consolidation surrounding a central area of ground-glass opacity. The bilateral, peripheral distribution is one of the features that helps distinguish COVID pneumonia from other types of viral or bacterial pneumonia on imaging.
How It’s Treated in the Hospital
Treatment for COVID pneumonia centers on two goals: fighting the virus and controlling the immune system’s overreaction.
For hospitalized patients who need supplemental oxygen, a corticosteroid called dexamethasone is standard. It dials down the inflammatory cascade that drives so much of the lung damage. An antiviral medication, remdesivir, is FDA-approved for hospitalized COVID patients and works by interfering with the virus’s ability to copy itself. It’s given intravenously, typically for about five days.
Oxygen support is escalated based on how well a patient responds. The progression generally moves from a simple nasal cannula to high-flow nasal oxygen to noninvasive ventilation (a tight-fitting mask that pushes air into the lungs). If a patient’s breathing rate stays above 30 breaths per minute or their oxygen levels remain critically low despite two hours on high-flow oxygen, mechanical ventilation through a breathing tube may become necessary. There are no rigid cutoffs for when to escalate, and clinical teams make judgment calls based on how hard the body is working to breathe.
Vaccines and Severe Pneumonia Risk
Vaccination significantly reduces the chance of developing severe COVID pneumonia. A WHO-cited study analyzing three years of data found that an up-to-date COVID vaccine received within the past six months was 72% effective at preventing COVID-related hospitalization and 67% effective at preventing the most severe outcomes, including ICU admission and death. The protection wanes over time, which is why booster doses are recommended for those at higher risk.
Recovery Timeline
For most people hospitalized with COVID pneumonia, the most dramatic healing happens in the first three months. CT scans show that lung abnormalities improve substantially during this window, with average damage scores dropping by roughly two-thirds between admission and the three-month mark. Further improvement continues between three and twelve months, though it’s more gradual. The median time for lung lesions to fully absorb is about 42 days after symptom onset, which is why follow-up imaging at three months is considered the best time to assess whether lasting damage is likely.
Fatigue and breathlessness, however, don’t always follow the same trajectory as the imaging. In one follow-up study, patients actually reported worse fatigue and shortness of breath scores at 12 months than they had at 3 months. This disconnect between improving scans and persistent symptoms is a hallmark of what many people experience as long COVID, and it suggests that the effects extend beyond what shows up on a CT scan.
Long-Term Lung Damage
More than a third of patients recovering from COVID pneumonia develop some degree of fibrotic changes, essentially scarring in the lung tissue. Nearly half show reduced ability to transfer oxygen from the lungs into the bloodstream, and about a quarter have measurably smaller lung capacity at follow-up. These numbers come from patients who were hospitalized, so they represent the more severe end of the spectrum. People with milder cases of COVID pneumonia generally fare better, though some degree of persistent respiratory limitation is possible even after moderate illness.
The scarring tends to develop in the same peripheral, lower-lung areas where the initial inflammation was worst. For some patients this stabilizes and causes minimal day-to-day impact. For others, it leads to ongoing exercise intolerance, breathlessness with exertion, or a persistent dry cough that can last months or longer.